KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Pacific Biosciences Of California (PACB) Cost of Revenue (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Cost of Revenue data on record, last reported at $28.1 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 3.73% year-over-year to $28.1 million; the TTM value through Dec 2025 reached $114.2 million, down 2.15%, while the annual FY2025 figure was $114.2 million, 2.15% down from the prior year.
  • Cost of Revenue reached $28.1 million in Q4 2025 per PACB's latest filing, up from $22.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $60.8 million in Q4 2021 and bottomed at $3.0 million in Q3 2022.
  • Average Cost of Revenue over 5 years is $27.0 million, with a median of $27.8 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: crashed 84.57% in 2022, then surged 1154.61% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $60.8 million in 2021, then crashed by 63.48% to $22.2 million in 2022, then skyrocketed by 119.63% to $48.8 million in 2023, then crashed by 40.22% to $29.2 million in 2024, then dropped by 3.73% to $28.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $28.1 million in Q4 2025, $22.5 million in Q3 2025, and $25.1 million in Q2 2025.